technology transforming life - cdn.ymaws.com · what is the optimal pathway for commercializtaion ?...
TRANSCRIPT
Technology Transforming Life
Technology Transforming Life
© Xomix 2018
LES USA Canada
Emerging Enterprise Committee Webinar
March 19th 2018
Licensing Executive Society USA Canada
Emerging Enterprise Committee
Commercialization: Building the Custom Fit for Success
Gary N. Keller, CLP
CEO - Xomix Ltd.
LESI – Life Science Committee Chair
LES USA Canada- Emerging Enterprise Chairman Emeritus
:
© Xomix 2018
LES USA Canada
Emerging Enterprise Committee Webinar
March 19th 2018
Commercialization into Startups
“Each company is a unique evolution
of a technology based opportunity…
This is the art of science”
© Xomix 2018
LES USA Canada
Emerging Enterprise Committee Webinar
March 19th 2018
What is the Optimal Pathway for
Commercializtaion ?
Determine if the IP based invention is:
– A Project
– A Product
– A Company
Develop a path for commercialization that optimizes the
value creation and impact.
Optimize through License or Incorporate or both?
© Xomix 2018
LES USA Canada
Emerging Enterprise Committee Webinar
March 19th 2018
Assessing the Technology
Identify the market niches for the technology
Determine the competition and competitive landscape
– Evaluate the competitive IP landscape for insight into other key
inventors, companies, and research institutions
– Evaluate key ongoing research that can lead to competitive
products and processes
– Speak with end-users to determine if there is an unmet need
and market demand
© Xomix 2018
LES USA Canada
Emerging Enterprise Committee Webinar
March 19th 2018
Assessing the Technology
Determine market size and market dynamics, including
drivers and barriers
Characterizes the technology’s likely commercial
potential and estimates market size and share
Speak with industry experts and companies in the
technology are to determine opportunities for
collaboration, licensing, and milestones for investment or
acquisition.
© Xomix 2018
LES USA Canada
Emerging Enterprise Committee Webinar
March 19th 2018
Assessing the Technology
Determine the alternatives
– Identify the current products and methods on the market, new
versions of existing products and new products in
development.
– Identify companies with capacity to accelerate development
into the area through modification of existing products.
© Xomix 2018
LES USA Canada
Emerging Enterprise Committee Webinar
March 19th 2018
Building the Commercialization Strategy
Develop a market entry strategy for the entry niche for
commercialization or licensing.
Company vs. Product Strategy
Actual vs. Virtual
Collaboration Strategies and Agreements
© Xomix 2018
LES USA Canada
Emerging Enterprise Committee Webinar
March 19th 2018
Building the Commercialization Team
Identify the “Dream Team”
Internal vs. External
Outsourced vs. Incubated
Structure the roles including responsibilities and benefits
• “Most biotech companies will change technologies.”
• “It is often easier to change the technology than the
team.”
© Xomix 2018
LES USA Canada
Emerging Enterprise Committee Webinar
March 19th 2018
Phase I - ZelleRx
NK-92 Technology
Granulocytes- White cells containing granules – Neutrophils
– Eosinophils
– Basophils
Lymphoid Cells- White cells containing no granules– Monocytes/Macrophages
– Lymphocytes
T-cells
B-cells
Natural Killer Cells*
*AKA- Large Granular Lymphocytes (have granules)
NK-92 A Proprietary Natural Killer Cell Line
Grants Awarded to NK-92 Programs
Federal Ministry of Education & Research, DE $2,109,210
Production Assistance for Cellular Therapies: $553,000
UPCI Allocated NCI Core Grant: $175,000
Jose Carreras Foundation: $650,000
Ontario Institute For Cancer Research: $475,000
RUSH University: $180,000
Sramek Center for Cell Therapy: $200,000
Coleman & Last Chance Foundations: $180,000
Grant Total: $4,519,210
(All non-dilutive except for RUSH)
US Phase I trial with NK-92
RCC = Renal Cell Carcinoma PD = Progressive Disease SD = Stable Disease * followed by allo
SCT MR = Mixed Response CIR = Clinical Response – marked reduction in one tumor site
All patients enrolled had advanced metastatic disease, with progressive cancer growth through last regimen despite multiple treatment
modalities including surgery, high-dose IL-2, interferon, radiation, chemotherapy, and stem cell transplantation. Clinical responses to a
single course of NK-92 monotherapy observed in the higher dose groups.
Diagnosis Cell dose/m2 Side Effects Outcome
1 RCC 1 x 10E8 0 SD*
2 RCC 1 x 10E8 0 PD
3 RCC 1 x 10E8 0 PD*
4 RCC 3 x 10E8 0 PD
5 RCC 3 x 10E8 0 PD
6 RCC 3 x 10E8 0 MR
7 RCC 1 x 10E9 0 PD*
8 RCC 1 x 10E9 0 SD
9 RCC 1 x 10E9 I - fever SD
10 Melanoma 3 x 10E9 III - fever CIR
11 RCC 3 x 10E9 IV - hypoglycemia SD
12 RCC 3 x 10E9 I - fever SD
Arai, et. al., Cytotherapy 10-6:625-632 2008
ZelleRx Leverage of Development Opportunities
- Cato Ventures – CRO Investment
- – up to $1M
- University of Pittsburgh – Clinical Development
- – up to $1M (not pursued)
© Xomix 2018
LES USA Canada
Emerging Enterprise Committee Webinar
March 19th 2018
Phase II - ConKwest
Out-Licensing Program
NK-92 cell lines serve as a QC and for testing.
– High degree of accuracy and reproducibility,
– Ease of maintenance and an inexhaustible supply,
– More accurate and reliable data at a fraction of the cost and effort,
– Competitive advantage in the race among companies to commercialize the next blockbuster antibody therapeutics.
Use the NK-92 family of cell-lines for non-therapeutic applications including quality testing for
– antibody production,
– antibody research and development,
– discovery research,
– patient testing.
© Xomix 2018
LES USA Canada
Emerging Enterprise Committee Webinar
March 19th 2018
Phase III - NantKwest
NantKwest™ is an innovative clinical-stage immunotherapy company
focused on harnessing the power of the innate immune system by
using the natural killer cell to treat cancer, infectious diseases and
inflammatory diseases.
© Xomix 2018
LES USA Canada
Emerging Enterprise Committee Webinar
March 19th 2018
Phase III - NantKwest
July 27, 2015 - NantKwest ($NK) priced its IPO at $25 a share, far
above the range, raising $207 million on the sale of 8.3 million
shares. Its shares opened at $37 and a that established a market cap
baseline at $2.6 billion.
© Xomix 2018
LES USA Canada
Emerging Enterprise Committee Webinar
March 19th 2018
Thank You!
Gary N. Keller, CLP
CEO, Xomix Ltd.
Chairman, LESI Life Science Committee
(773) 251-8214
Technology Transforming Life